Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts

The majority of breast cancers are estrogen receptor positive (ER+). Blockade of estrogen biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine therapy for post-menopausal women with ER+ breast cancers. However, AI resistance remains a major challenge. We have demonstrated previousl...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreucci, Elena, Francica, Paola, Fearns, Antony, Martin, Lesley-Ann, Chiarugi, Paola, Isacke, Clare M., Morandi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348339/
https://www.ncbi.nlm.nih.gov/pubmed/27602955
http://dx.doi.org/10.18632/oncotarget.11826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348339/
https://www.ncbi.nlm.nih.gov/pubmed/27602955
http://dx.doi.org/10.18632/oncotarget.11826

Ejemplares similares